Therefore, FSTL3 is considered as a potential biomarker of immunotherapeutic efficacy and a novel immunotherapeutic target in CRC patients, particularly in ICB-resistant MSI-H CRC patients. This evidence concerns the gene FSTL3 and colorectal carcinoma.